Illumina (NSDQ:ILMN) announced today that it entered into an agreement to acquire Grail for cash and stock consideration of $8 billion. Last week, it was reported that Illumina was looking to purchase the cancer detection startup that spun out from the company four years ago and the companies confirmed that to be true today. Grail was […]
Illumina may buy back Grail
Illumina (NSDQ:ILMN) may acquire Grail for more than $8 billion — four years after it spun out the cancer detection startup. That’s according to a Bloomberg report out yesterday, which cited people familiar with the matter. Analysts told Bloomberg that the acquisition would put Illumina — a giant in the DNA sequencing space — in direct […]
NIH to boost COVID-19 testing capabilities
The National Institutes of Health announced a $129.3 million plan to support scaling and manufacturing for COVID-19 tests. As part of its Rapid Acceleration of Diagnostics (RADx) initiative, NIH is awarding contracts to nine companies for their technologies that include portable point-of-care tests for immediate results and high-throughput laboratories that can produce results in 24 […]
Illumina gains FDA EUA for sequencing-based COVID-19 test
Illumina (NSDQ:ILMN) announced that it received FDA emergency use authorization (EUA) for its COVIDSeq sequencing-based COVID-19 diagnostic test. COVIDSeq uses upper respiratory specimens, such as a nasopharyngeal or oropharyngeal swab, and delivers sample receipt to result in 24 hours with the NovaSeq 6000 sequencing system, according to a news release. Illumina’s high-throughput, in vitro diagnostic test […]
Bristol-Myers Squibb, Illumina to develop companion diagnostics for immunotherapies
Bristol-Myers Squibb (NYSE:BMY) is joining forces with Illumina (NSDQ:ILMN) to develop and commercialize diagnostic tests to support Bristol’s portfolio of cancer drugs. The companies announced last week that they plan to develop an assay to measure predictive genomic biomarkers, like tumor mutation burden, that could help doctors identify patients that will benefit from Bristol’s immunotherapies. Get the full […]
Illumina, Loxo Oncology partner for next-gen pan-cancer companion diagnostics
Illumina (NSDQ:ILMN) and Loxo Oncology (NSDQ:LOXO) are teaming up to develop a multi-gene panel for broad tumor profiling. The two companies ultimately hope to sell a next-gen sequencing-based companion diagnostic that will boast a pan-cancer indication. Illumina and Loxo plan to seek approval for a version of Illumina’s TruSight Tumor 170 test as a companion […]
Skyline Medical to take 20% stake in Helomics, license Illumina’s gene sequencing tech
Fresh from its purchase of a 20% stake in joint venture partner Helomics, Skyline Medical (NSDQ:SKLN) said today that it inked a deal to license the MiSeqDx next-generation sequencing technology from Illumina (NSDQ:ILMN). Yesterday Minneapolis-based Skyline said it agreed to buy a lump of convertible shares representing 20% of Helomics, in exchange for 1.1 million newly issued SKLN shares, which […]
Philips, Illumina to launch precision medicine cancer program with Navican
Royal Philips (NYSE:PHG) and Intermountain Healthcare company Navican inked an agreement today to launch a precision health informatics solution aimed at improving outcomes for late stage cancer patients. The program is slated to leverage Navican‘s TheraMap Precision Cancer Care services and Philips’ IntelliSpace Genomics platform, which uses Illumina‘s next-gen genomic sequencing technologies. At Utah-based Intermountain Healthcare’s […]
Illumina, Novogene ink development deal for next-gen sequencing tech
Illumina (NSDQ:ILMN) and genomic service company Novogene said today they entered into an agreement to jointly develop advanced clinical applications for reproductive health and oncology based on next-generation sequencing technology. The collaboration will focus on providing advanced, integrated sequencing solutions to the clinical market, the company said. The 2 companies are slated to work together to create […]
Illumina unveils highly sought $1,000 genome system | MassDevice.com On Call
MASSDEVICE ON CALL — California-based lifesciences firm Illumina’s (NSDQ:ILMN) this week unveiled that it had achieved the highly sought $1,000 mark for human DNA sequencing.
Dick Cheney as a road map for heart tech | MassDevice.com On Call
MASSDEVICE ON CALL — Former Vice President Dick Cheney’s long-running battle with heart disease also traces the evolution of cardiovascular medical technologies.
The New York Times traced Cheney’s heart history as it correlated to important milestones in medicine, from his 1st heart attack at age 37 to the heart transplant he received last month.
Cheney was one of the relatively early recipients of quadruple bypass surgery in 1988 and a cardiac stent in 2000.
